Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Feb 7, 2017
The importance of Josep’s work at the Biocomplexity Institute cannot be overstated. Many of us – if we are not affected ourselves – know someone who suffers from a gastrointenstinal autoimmune disease, such as Crohn’s, IBD, and ulcerative colitis. As Josep explains in his talk “Accelerated Path to Cures,” the treatment for these diseases is inefficient and new ways of developing pharmalogical treatment should be investigated.
Dr. Josep Bassaganya-Riera is a professor at the Biocomplexity Institute of Virginia Tech., an entrepreneur and investor. He is the scientific founder of BioTherapeutics, a biotech Company that develops oral therapeutics for autoimmune diseases and diabetes. Dr. Bassaganya-Riera directs the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Tech, where he employs computational and mathematical models of the gut immune system in combination with preclinical and clinical experimentation to gain mechanistic insights about the gut immune system and to develop new therapeutics for gastrointestinal diseases. He has over 17 years of preclinical, mechanistic and translational research experience in immune-mediated, infectious and inflammatory diseases, published over 120 peer-reviewed papers, has 15 patents and has secured over $18 million in funding from NIH grants and contracts, industrial partners, and equity financing.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx